{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-000990","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.506262+00:00","generated_at":"2026-06-27T00:48:42.196850+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entera Bio reports $12.2M net loss for 2021; guides FY2022 operating loss of $25-30M; EB613 Phase 3 trial in 2022","bullets":["Revenue $571k in 2021 vs $365k in 2020; net loss $12.2M ($0.47 per share) vs $11.2M ($0.67 per share).","Cash $24.9M at Dec 31, 2021; $21.7M at Mar 1, 2022; expects FY2022 operating loss $25-30M.","EB613 (osteoporosis) Phase 3 pivotal trial expected to start in 2022 after positive FDA End of Phase 2 meeting.","EB612 (hypoparathyroidism) improved formulation; next clinical trial planned in 2022; Orphan Drug status FDA and EMA.","Engaged Torreya Capital as financial advisor for non-dilutive strategic alliances for EB613."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-000990","json":"https://secwatch.observer/filing/0001178913-22-000990.json","markdown":"https://secwatch.observer/filing/0001178913-22-000990.md","text":"https://secwatch.observer/filing/0001178913-22-000990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/0001178913-22-000990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:48:42.196850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}